In the landmark EMILIA trial, T-DM1 showed strong clinical efficacy in patients with HER2-positive breast cancer that was resistant to trastuzumab, achieving an objective response rate of 43.6% and a median PFS of 9.6 months with a reported rate of adverse events grade 3 or above of 41% [131]. This evidence concerns the gene ERBB2 and breast carcinoma.